Comparing the current results to its competitors, Schrodinger Inc reported Revenue increase in the 2 quarter 2026 by 7.54 % year on year, while most of its competitors have experienced contraction in revenues by -0.3 %, achieved in the same quarter.
Schrodinger Inc 's Comment on Competition and Industry Peers
The company focuses on physics-based computational drug discovery and aims to advance its computational platform and software. It has initiated a predictive toxicology project funded by the Bill & Melinda Gates Foundation. In drug development, its compound SGR-3515 demonstrated superior anti-tumor activity and target engagement compared to competitors ZN-c3 and RP-6306. The molecular discovery and design software market is global and competitive, with key factors including accuracy, customer satisfaction, ease of use, functionality, brand reputation, technology platform, integration, security, scalability, cost, innovation, and compatibility with legacy systems. The company competes with providers of simulation and modeling software to biopharmaceutical companies, including BIOVIA (a brand of Dassault Systèmes SE), Chemical Computing Group (US) Inc., Cresset Biomolecular Discovery Limited, and Cadence Design Systems. It considers the high investment and expertise required as barriers to new entrants in the market.
With revenue growth of 7.54 % within Overall company, Schrodinger Inc achieved improvement in market share, within Overall company to approximately 6.4 %. << More on SDGR Market Share.
*Market share is calculated based on total revenue.
September 18, 2025
Schrodinger, Inc., a leader in pharmaceutical computational science, continues to make strategic moves that enhance its competitive edge in the rapidly evolving drug discovery landscape. Recent inducement grants and a significant expansion in collaboration with Ajax Therapeutics highlight the company’s dual focus on building a talented workforce and advancing its research capabilities. This article interprets recent announcements from Schrodinger related to inducement grants under Nasdaq Listing Rule 5635(c)(4) and the enhancement of their partnership with Ajax Therapeutics analyzing their implications for the company’s future trajectory. In the pharmaceutical and biotech industry, the talent acquisit...
July 17, 2025
Expanding Horizons: Ajax Therapeutics and Schrodinger Enhance Collaboration to Target New JAK Inhibitors and Drive Innovation in Cancer Research In a significant advancement for drug development, Ajax Therapeutics, Inc. and Schrodinger, Inc. (Nasdaq: SDGR) have announced an expansion of their longstanding collaboration, now encompassing a new Janus kinase (JAK) target. This strategic partnership, originally established in 2019, aims to leverage Schrodinger’s advanced computational platform alongside Ajax’s structural biology insights to create and advance a robust pipeline of novel therapeutic molecules, particularly focusing on JAK inhibitors. Overview of JAK Inhibitors and Their Clinical ImportanceJanu...
Absci Corp's business model focuses on driving innovation in drug discovery and development through their integrated synthetic biology platform. They offer a comprehensive suite of services that enable clients to rapidly and efficiently discover, develop, and manufacture new biotherapeutics.
Recursion Pharmaceuticals Inc is a biotech company that utilizes its artificial intelligence (AI) platform to identify and develop potential drug candidates. They employ a unique approach by combining AI technology with experimental biology and automation to accelerate drug discovery. Recursion applies its platform to identify new treatments for rare diseases and have established partnerships with various organizations in the pharmaceutical industry.
Cue Biopharma Inc is a biopharmaceutical company that focuses on developing a novel class of medicines called Immuno-STATs. Their business model involves utilizing the body's immune system to target and treat a wide range of diseases, including cancer, autoimmune disorders, and viral infections. They collaborate with strategic partners and employ their expertise in immunology, protein engineering, and synthetic biology to develop these innovative therapies.
Sources:
Schrodinger Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Schrodinger Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
